Why Twist Bioscience Stock Skyrocketed This Week

Why Twist Bioscience Stock Skyrocketed This Week

Eric Volkman, The Motley Fool

Sat, September 19, 2026 at 2:56 AM GMT+3 2 min read

Biotech stocks are famously volatile, due to the speculative nature of the drug discovery business. The good news about this is that when one reports good news, it can send its stock into the stratosphere.

On Wednesday, Twist Bioscience (NASDAQ: TWST) had an excellent development to divulge and investors plowed into the biotech company's stock. As a result, it finished the week up by more than 31%.

Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Getting in tune

Before market open that day, Twist announced that it had reached an agreement to participate in Lilly TuneLab. This is an advanced drug discovery initiative from U.S. pharmaceutical giant Eli Lilly, perhaps best known among the public these days for its Zepbound obesity treatment.

Twist will provide antibody characterization data services for TuneLab, the company said. It added that this will include AbLab, an antibody developability prediction model.

TuneLab utilizes artificial intelligence (AI) and machine learning trained on many years of Eli Lilly's proprietary research data. TuneLab participants can use the system's models to screen candidate molecules for developement.

It quoted co-founder and CEO Emily Leproust as saying that "users can select preferred protocols to generate high-quality data with preferred pricing -- both helping them to more efficiently select antibody sequences against their targets and contribute that data back to TuneLab for federated training."

More than 1 winner

This feels like a clear win-win not only for Twist and Eli Lilly but also for the broader biotech space. I don't see many negatives with the biotech tapping into such a large and powerful research and discovery system -- and drawing revenue from it -- so I'd be very bullish on its future efforts.

Should you buy stock in Twist Bioscience right now?

Before you buy stock in Twist Bioscience, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Twist Bioscience wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $406,141!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,347,745!*

Now, it's worth noting Stock Advisor's total average return is 940% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 18, 2026.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Twist Bioscience. The Motley Fool has a disclosure policy.

Why Twist Bioscience Stock Skyrocketed This Week was originally published by The Motley Fool